Dyax Corp (DYAX) – Company Press Releases
-
Shire Completes Acquisition of Dyax
-
Dyax Corp. Sets January 21, 2016 As Date of Special Stockholder Meeting To Vote On Its Proposed Acquisition By Shire plc
-
Dyax Corp. Presents DX-4012 Data at the 2015 American Society of Hematology Annual Meeting
-
Dyax Corp. Announces Early Termination of Hart-Scott-Rodino Waiting Period
-
Dyax Corp. Recognized as a “Top Place to Work” by The Boston Globe for Second Year in a Row
-
Dyax Corp. Presents Phase 1b DX-2930 Data at the American College of Allergy, Asthma, and Immunology Annual Meeting
-
Law Offices of Marc S. Henzel Announces Investigations of Globus Medical, Inc., USA Technologies, Inc., Constant Contact, Inc., Dyax Corp, Hutchinson Technology and MedAssets, Inc.
-
Dyax Corp. Announces Cancellation of Research and Development Day
-
Shire to Acquire Dyax Corp, Expanding and Extending Industry-Leading Hereditary Angioedema (HAE) Portfolio
-
Dyax Corp. Announces Third Quarter 2015 Financial Results
-
Dyax Corp. to Review Third Quarter 2015 Financial Results at Research and Development Day
-
Dyax Corp. to Webcast 2015 Research and Development Day
-
Dyax Corp. to Host Third Quarter 2015 Financial Results Call and Webcast
-
Dyax Corp. Receives Positive Opinion for Orphan Medicinal Product Designation in the European Union for DX-2930 for the Treatment of Hereditary Angioedema
-
Dyax Corp. to Participate in the Leerink Partners 4th Annual Rare Disease Roundtable
-
Dyax Corp. to Participate in the Morgan Stanley Global Healthcare Conference
-
Dyax Corp. Provides Update on DX-2930 Clinical and Commercial Supply Initiatives
-
Dyax Corp. to Participate in the 2015 Wedbush PacGrow Healthcare Conference
-
Dyax Corp. Announces Second Quarter 2015 Financial Results
-
Dyax Corp. to Host Second Quarter 2015 Earnings Call and Webcast
-
Dyax Corp. Receives FDA Breakthrough Therapy Designation for DX-2930 for Prevention of Attacks of Hereditary Angioedema
-
Dyax Corp. Presents Phase 1b DX-2930 Data at the 2015 European Academy of Allergy and Clinical Immunology Annual Congress
-
Dyax Corp. to Participate in the Jefferies 2015 Global Healthcare Conference
-
Dyax and the U.S. Hereditary Angioedema Association (HAEA) Launch the HAE Hope® Essay Contest on the Fourth Annual Hereditary Angioedema Day
-
Dyax Corp. Appoints Dr. Abbie Celniker to Board of Directors
-
Dyax Corp. to Participate in Upcoming Investor Conferences
-
Dyax Corp. Announces First Quarter 2015 Financial Results
-
Dyax Corp. to Host First Quarter 2015 Earnings Call and Webcast
-
Dyax Closes $230 Million Public Offering of Common Stock
-
Dyax Corp. to Participate in the 14th Annual Needham Healthcare Conference
-
Dyax Announces Pricing of $200 Million Public Offering of Common Stock
-
Dyax Announces Proposed Public Offering of 7,000,000 Shares of Common Stock
-
Dyax Announces Positive Results from Phase 1b Clinical Trial of DX-2930
Back to DYAX Stock Lookup